Switch theme
Sign up to access all valuation multiples
JETEMA Co Ltd is a bio venture company. It offers products such as Botulinum toxin, Filler, Anti-aging solutions. The company also offers medical devices and cosmetics.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
JETEMA Co. has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, JETEMA Co. achieved revenue of $46.7M and an EBITDA of $10.5M.
JETEMA Co. expects next 12-month revenue of XXX and NTM EBITDA of XXX
See JETEMA Co. valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $40.0M | $46.7M | XXX | XXX | XXX |
| Gross Profit | $15.2M | $19.3M | XXX | XXX | XXX |
| Gross Margin | 38% | 41% | XXX | XXX | XXX |
| EBITDA | $15.2M | $10.5M | XXX | XXX | XXX |
| EBITDA Margin | 38% | 23% | XXX | XXX | XXX |
| Net Profit | $1.0M | $9.5M | XXX | XXX | XXX |
| Net Margin | 2% | 20% | XXX | XXX | XXX |
| Net Debt | $58.6M | $56.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 25, 2025, JETEMA Co.'s stock price is KRW 7370 (or $5).
JETEMA Co. has current market cap of KRW 264B (or $180M), and EV of KRW 358B (or $244M).
See JETEMA Co. trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $244M | $180M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 25, 2025, JETEMA Co. has market cap of $180M and EV of $244M.
JETEMA Co.'s trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate JETEMA Co.'s 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for JETEMA Co. and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $244M | XXX | XXX | XXX |
| EV/Revenue | 5.2x | XXX | XXX | XXX |
| EV/EBITDA | 23.1x | XXX | XXX | XXX |
| P/E | -1400.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -70.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpJETEMA Co.'s NTM/LTM revenue growth is n/a
JETEMA Co.'s revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, JETEMA Co.'s ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate JETEMA Co.'s 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for JETEMA Co. and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 17% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -31% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 9% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 14% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 43% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Acme United | XXX | XXX | XXX | XXX | XXX | XXX |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Live Verdure | XXX | XXX | XXX | XXX | XXX | XXX |
| Lavipharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Sarantis Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
JETEMA Co. acquired XXX companies to date.
Last acquisition by JETEMA Co. was XXXXXXXX, XXXXX XXXXX XXXXXX . JETEMA Co. acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was JETEMA Co. founded? | JETEMA Co. was founded in 2009. |
| Where is JETEMA Co. headquartered? | JETEMA Co. is headquartered in South Korea. |
| Is JETEMA Co. publicy listed? | Yes, JETEMA Co. is a public company listed on KRX. |
| What is the stock symbol of JETEMA Co.? | JETEMA Co. trades under 216080 ticker. |
| When did JETEMA Co. go public? | JETEMA Co. went public in 2019. |
| Who are competitors of JETEMA Co.? | Similar companies to JETEMA Co. include e.g. Acme United, EZZ Life Science, Live Verdure, Lavipharm. |
| What is the current market cap of JETEMA Co.? | JETEMA Co.'s current market cap is $180M |
| What is the current revenue growth of JETEMA Co.? | JETEMA Co. revenue growth between 2023 and 2024 was 17%. |
| Is JETEMA Co. profitable? | Yes, JETEMA Co. is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
